Regulus Therapeutics Inc (RGLS) Touches $2.78: At This Price, The Risk Is Worth It

Regulus Therapeutics Inc (NASDAQ:RGLS) concluded the trading at $2.78 on Thursday, March 21 with a rise of 11.20% from its closing price on previous day.

Taking a look at stock we notice that its last check on previous day was $2.50 and 5Y monthly beta was reading 1.44. Considering stock’s 52-week price range provides that RGLS hit a high price of $3.79 and saw its price falling to a low level of $0.77 during that period. Over a period of past 1-month, stock came adding 84.11% in its value.

With its current market valuation of $56.60 million, Regulus Therapeutics Inc is set to declare its quarterly results on May 09, 2024 – May 13, 2024. Analysts are in estimates of -$0.39 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -$1.58 for 2023 with estimates of that growing to -$0.52 in next year. These estimates are suggesting current year growth of 15.10% for EPS and 67.10% growth next year.

In last 7 days, analysts came adjusting their opinions about stock’s EPS with 1 upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review RGLS stock’s current outlook then short term indicators are assigning it an average of 100% Buy, while medium term indicators are categorizing the stock at an average of 100% Buy. Long term indicators are suggesting an average of 100% Buy for it.

Digging deeper we become aware of the PEG ratio of the RGLS stock which is currently positioned at 0. It further provides that stock’s current price level is 56.11% away from its 20-day simple moving average and is 82.88% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 77.11 while volatility remained at 17.16% over the past week which changes to 15.97% when measuring it over the past month. Beta is valued at 1.51, while measure of average true range or ATR is currently at 0.33.

Having a second look at Regulus Therapeutics Inc (NASDAQ:RGLS) provides that stock’s average daily trading volume for 3 months was 2.99 million, while it jumped to 18.16 million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 20.36 million.

The percentage of outstanding shares held by the insiders is 13.83% while it is 45.04% for the institutional holders. The figures also indicate that as of Feb 29, 2024, number of stock’s short shares was 54880.0 which implies a short ratio of 1.03. This shows down a 0.27% of Short Interest in company’s outstanding shares on the day. In February the standing of shares short improved as it was 0.12 million in the previous month. Addition of 117.19% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.

Most Popular